Cagrilintide 5 mg
Educational recon guide for a 5 mg Cagrilintide research vial and weekly unit mapping. Research use only — investigational amylin analogue.
Vial size
Same research phases — calculator defaults and unit math match the selected vial strength.
Vial
5 mg
Your BAC water
1 mL
Concentration
5.00 mg/mL
Per unit
~50.0 mcg
Frequency
Once weekly (same weekday)
Route
Subcutaneous
Live reconstitution calculator
Defaults match this guide (5 mg + 1 mL BAC). Change water or dose and the unit tables below update automatically.
Step 1
Reconstitution
Peptide amount in the vial and how much bacteriostatic water you add.
Step 2
Your dose
This guide uses microgram-scale research doses — quick picks are in mcg (100 mcg = 0.1 mg).
Quick select (mcg) — switch units or type any value
Suggested: 30-unit barrel (smallest that fits this draw).
Your draw
Results
Total draw
5 units
Volume
0.050 mL
Doses per vial
20
Syringes needed
1
Barrel
30-unit
Fits one syringe?
Yes
30-unit · 0.3 mL
Filled to 5 u
Fill one 30-unit U-100 syringe to about 5 units (0.050 mL).
Weekly research phases
Units and volumes recompute from your Step 1 concentration (1 mL BAC → 5.00 mg/mL · 50.0 mcg/unit).
Standard titration
Published research titrations commonly start around ~0.25–0.3 mg once weekly and step upward (examples include ladders toward ~2.4 mg weekly, with higher monotherapy arms studied up to ~4.5 mg weekly). GI tolerability drives slow titration.
| Phase | Weekly dose | Units | Volume |
|---|---|---|---|
| Weeks 1–4 | 250 mcg0.25 mg | 5 u | 0.05 mLCommon educational start (~0.25 mg weekly) |
| Weeks 5–8 | 500 mcg0.5 mg | 10 u | 0.10 mL |
| Weeks 9–12 | 1 mg1,000 mcg | 20 u | 0.20 mL |
| Weeks 13–16 | 1.70 mg1,700 mcg | 34 u | 0.34 mL |
| Weeks 17+ | 2.40 mg2,400 mcg | 48 u | 0.48 mLCommon maintenance discussion range in dual-pathway obesity research |
Advanced / higher-end
Faster escalation discussed in research communities — not a clinical recommendation
| Phase | Weekly dose | Units | Volume |
|---|---|---|---|
| Higher monotherapy arm · 4.5 mg weekly | 4.50 mg4,500 mcg | 90 u | 0.90 mLUpper end of some monotherapy dose-finding work — check syringe capacity vs recon water |
Supplies planner
Using the guide’s phase ladder (250 mcg → 500 mcg → 1 mg weekly (phase ladder)) over a 12-week schedule. Set a dose in Step 2 to plan supplies at your own amount.
Your recon
1 mL · 5.00 mg/mL
Dose in plan
Phase ladder
Syringe size
100-unit
Horizon
12-week schedule
Cagrilintide 5 mg vials
2 vials
~7 mg mg total peptide over this 12-week schedule at 250 mcg → 500 mcg → 1 mg weekly (phase ladder). Each vial holds 5 mg.
Bacteriostatic water
1 × 3 mL bottle
1 mL BAC per vial × 2 vials = 2.0 mL total. Buy as 1× 3 mL bottle or 1× 10 mL bottle (whichever you stock).
U-100 insulin syringes (100-unit)
12+ syringes
About one 100-unit syringe per injection for this schedule. Keep a few spares.
Alcohol swabs & sharps
~28 swabs · 1 sharps container
Wipe vial stopper and injection site each time. Dispose needles in a proper sharps container.
Reconstitution steps
- Allow the lyophilized 5 mg Cagrilintide vial and bacteriostatic water to reach room temperature.
- Draw 1.0 mL bacteriostatic water (default for this guide).
- Inject BAC slowly down the inner wall of the vial — avoid blasting the powder cake.
- Gently swirl or roll until the solution is clear. Do not shake hard (foaming).
- Label with recon date and concentration (e.g. "5.0 mg/mL — 1 mL BAC").
- Refrigerate at 2–8 °C (35–46 °F), protected from light. Prefer using a reconstituted multi-dose vial within ~28 days with sterile technique.
Storage
Lyophilized
Keep dry powder cold and dark when possible (−20 °C / −4 °F preferred for long-term research stock).
Reconstituted
Refrigerate at 2–8 °C (35–46 °F). Avoid freeze–thaw of the working solution. Prefer finishing within ~28 days.
- ·Write recon date and BAC volume on the label.
- ·Protect from light during storage.
- ·Discard if cloudy, particulates, or odd odor appear after reconstitution.
Protocol notes
- ·Cagrilintide is a long-acting amylin analogue studied for obesity (alone and with GLP-1 agonists).
- ·Research powders are not the same as clinical trial drug product.
- ·Often discussed with semaglutide (CagriSema) — see the Cagri+Sema blend guides for fixed dual vials.
- ·Research use only.
Research context & considerations
Cagrilintide activates amylin pathways involved in satiety and gastric emptying. Clinical development includes monotherapy and combination programs with semaglutide. Catalog research vials are educational recon materials only.
- ·GI effects (nausea, etc.) are commonly discussed for amylin/GLP-1 pathway agents.
- ·Not FDA-approved as a research-vial consumer product.
- ·Pregnancy and pediatric use out of scope.
Catalog match
Cagrilintide (CGL5)
5mg x 10 vials · from $45